Mechanism of Action
KISS1R/GPR54 Activation
Kisspeptin-54 binds KISS1R (GPR54), a Gq/G11-coupled GPCR expressed on GnRH neurons in the hypothalamus. Receptor activation induces phospholipase C activity, IP3-mediated calcium release, and ERK phosphorylation. This depolarizes GnRH neurons and triggers action potential firing, driving pulsatile GnRH release into the hypophyseal portal circulation.
Differential Potency vs. KP-10
While kisspeptin-10 (the short 10-residue form) is commonly used in research, KP-54 has a longer plasma half-life (~28 minutes vs. ~3 minutes for KP-10) and greater potency in stimulating LH release, particularly in infertility clinical settings. The longer half-life of KP-54 allows sustained stimulation of GnRH neurons for clinical trigger use.
Research Summary
IVF Trigger
Phase 2Phase 2 trials evaluated KP-54 as an oocyte maturation trigger in IVF cycles, replacing hCG. A single IV dose of KP-54 induced endogenous LH surges comparable to standard hCG triggers. This approach may reduce ovarian hyperstimulation syndrome (OHSS) risk by producing a self-limiting LH surge rather than sustained hCG exposure.
Hypothalamic Amenorrhea
Phase 2Women with hypothalamic amenorrhea show significantly reduced kisspeptin signaling. Pulsatile KP-54 infusion restores GnRH pulsatility and LH secretion in these patients. A Phase 2 trial showed subcutaneous KP-54 administration twice daily restored menstrual cycles in women with functional hypothalamic amenorrhea.
Calculate your Kisspeptin-54 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| IVF oocyte trigger | 9.6 nmol/kg IV | Single bolus | Intravenous |
| Hypothalamic amenorrhea | 1-5 nmol/kg SC | Twice daily x 8 weeks | Subcutaneous |
Clinical trial use. Not commercially available as standalone product.
Interactions
Safety Profile
KP-54 is well tolerated in clinical trials. Adverse effects include flushing, mild headache, and transient hypotension from vasodilation. No significant ovarian hyperstimulation syndrome (OHSS) in IVF trigger studies. Self-limiting LH surge profile improves the OHSS safety profile versus hCG. No arrhythmias or hepatotoxicity reported.
References
- [1]Jayasena CN et al. (2014). Subcutaneous injection of kisspeptin-54 accurately induces oocyte maturation and luteinization in women undergoing in vitro fertilization. Journal of Clinical Endocrinology and Metabolism, 99(12), E2406-E2415.
- [2]Jayasena CN et al. (2014). Twice-weekly kisspeptin-54 administration induces menstrual cycles in hypothalamic amenorrhoea. Clinical Endocrinology, 81(5), 694-701.